Session

Improving prostate cancer staging and outcomes after radical prostatectomy

Poster Session 80

  • Location:
    Room Madrid, North Hall (Level 1)
  • Chairs:
     G. Gandaglia, Milan (IT)
     D. Murphy, Melbourne (AU)
     G. Palapattu, Ann Arbor (US)
  • Aims and objectives of this session

    The aim of this session is to discuss on how to improve prostate cancer staging and outcomes after surgery.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
1057
Lymphadenectomy trends in Gleason 7 prostate cancer: A population-based study

By: Chandrasekar T., Goldberg H., Klaassen Z., Hamilton R., Fleshner N., Kulkarni G.

Institutes: University Health Network, Division of Urology, Dept. of Surgical Oncology, Toronto, Canada

1058
Population-based analysis: Changes in the natural history of low risk localized prostate cancer

By: Helgstrand J.T.1, Klemann N.1, Toft B.G.2, Vainer B.2, Røder M.1, Iversen P.1, Brasso K.1

Institutes: 1Copenhagen University Hospital, Rigshospitalet, Copenhagen Prostate Cancer Center, Dept. of Urology, Copenhagen, Denmark, 2Copenhagen University Hospital, Rigshospitalet, Dept. of Pathology, Copenhagen, Denmark

1059
Non-prostate cancer mortality following radical prostatectomy or radiotherapy in men with localized and locally advanced prostate cancer: An analysis using propensity score matching

By: Kim S.I.1, Kim S.J.1, Choo S.H.1, Cho D.S.2

Institutes: 1Ajou University School of Medicine, Dept. of Urology, Suwon, South Korea, 2Bundang Jesaeng Hospital, Dept. of Urology, Seongnam, South Korea

1060
Oncologic long-term outcome in patients with pathologic Gleason 3+3 score at radical prostatectomy

By: Mandel P.1, Graefen M.2, Pompe R.2, Chun F.3, Salomon G.2, Huland H.2, Tilki D.1

Institutes: 1University Hospital Hamburg-Eppendorf, Martini-Clinic Prostate Cancer Center, Department of Urology, Hamburg, Germany, 2University Hospital Hamburg-Eppendorf, Martini-Clinic Prostate Cancer Center, Hamburg, Germany, 3University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany

1062
Cost effectiveness comparison between neoadjuvant chemo-hormonal therapy and extended lymph node dissection in patients with high-risk prostate cancer

By: Hagiwara K.1, Hatakeyama S.1, Tobisawa Y.1, Yoneyama T.1, Imai A.1, Yoneyama T.1, Hashimoto Y.1, Koie T.1, Tsuchiya N.2, Habuchi T.3, Arai Y.4, Ohyama C.1

Institutes: 1Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, 2Yamagata University, Faculty of Medicine, Dept. of Urology, Yamagata, Japan, 3Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan, 4Tohoku University Graduate School of Medicine, Dept. of Urology, Sendai, Japan

1063
Retrograde perfusion sphinterometry to evaluate efficacy of autologous 6-branch suburethral sling to properly restore sphincteric apparatus during robotic assisted radical prostatectomy (RALP)

By: Cestari A., Lolli C., Ghezzi M., Sangalli M., Zanoni M., Fabbri F., Sozzi F., Zanni G., Dell’Acqua V., Rigatti P.

Institutes: Istituto Auxologico Italiano, Dept. of Urology, Milan, Italy

1064
Transurethral catheter removal on postoperative day 2 after robot-assisted laparoscopic radical prostatectomy: A feasibility study from a single high-volume referral centre

By: Brassetti A., Emiliozzi P., Cardi A., De Vico A., Iannello A., Pansadoro A., Scapellato A., Riga T., D’Elia G.

Institutes: San Giovanni Addolorata Hospital, Dept. of Urology, Rome, Italy

1065
Visibility of characterized periprostatic nerve distributions for nerve-sparing radical prostatectomy

By: Sievert K-D.1, Hennenlotter J.2, Dillenberg T.2, Kuehs U.2, Wollner J.3, Kunit T.4, Zweers P3, Andersson K-E.5, Pannek J.3, Amend B.2

Institutes: 1Paracelsus Private Medical University of Salzburg, Dept. of Urology and Andrology, Salzburg, Austria, 2University of Tübingen, Dept. of Urology, Tübingen, Germany, 3Swiss Paraplegic Center, Dept. of Neuro-Urology, Nottwil, Switzerland, 4SALK, Dept. of Urology, Salzburg, Austria, 5Aarhus University, Dept. of Clinical Medicine, Aarhus, Denmark

1066
Oncological and functional outcome after radical prostatectomy in men ≤45 years of age

By: Mandel P., Angerer M., Haese A., Salomon G., Rosenbaum C., Veleva V., Graefen M., Huland H., Tilki D.

Institutes: University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center; Dept. of Urology, Hamburg, Germany

1067
A randomized control trial on the impact of regional hypothermia: Ad hoc analysis on short term recovery of sexual function after robot-assisted radical prostatectomy (RARP)

By: Ko Y-H.2, Osann K.3, Skarecky D.1, Morales B.1, Ahlering T.1

Institutes: 1University of California, Irvine, Dept. of Urology, Orange, United States of America, 2Yeoungnam University, Dept. of Urology, Yeoungnam, South Korea, 3University of California, Irvine, Dept. of Medicine, Orange, United States of America

1068
The prognostic role of sentinel node dissection on biochemical recurrence-free survival rate of prostate cancer patients after robot-assisted radical prostatectomy

By: Grivas N.1, Wit E.1, Bex A.1, Hendricksen K.1, Horenblas S.1, Kleinjan G.1, Van Rhijn B.1, Vegt E.2, Van Der Poel H.1

Institutes: 1Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, 2Netherlands Cancer Institute, Dept. of Nuclear Medicine, Amsterdam, The Netherlands

1069
Fluorescence supported lymph node dissection in robot-assisted radical prostatectomy – a prospective randomized clinical trial

By: Harke N.N.1, Wagner C.2, Schuette A.2, Addali M.2, Urbanova K.2, Fangmeyer B.2, Witt J.H.2

Institutes: 1University of Rostock, Dept. of Urology, Rostock, Germany, 2St. Antonius Hospital, Prostate Center Northwest, Dept. of Urology, Pediatric Urology and Urologic Oncology, Gronau, Germany

Summary
 D. Murphy, Melbourne (AU)